Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 9, 2011, Pages 623-631

  Campbell, Duncan J ^a,b   Zhang, Yuan ^b   Kelly, Darren J ^b   Gilbert, Richard E ^d   McCarthy, Davis J ^c   Shi, Wei ^c   Smyth, Gordon K ^c  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Aliskiren; Angiotensin; Bradykinin; Kallikrein; Renin inhibition

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN II; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; PERINDOPRIL; RENIN; TISSUE KALLIKREIN;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; KIDNEY; LUNG; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; TRANSGENIC RAT; TREATMENT DURATION;

ALDOSTERONE; AMIDES; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; BRADYKININ; FEMALE; FUMARATES; HEART; KALLIKREINS; KIDNEY; LUNG; MICE; MYOCYTES, CARDIAC; PERINDOPRIL; RATS; RATS, SPRAGUE-DAWLEY; RENIN; RNA, MESSENGER; TISSUE KALLIKREINS;

EID: 80052081122     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05572.x     Document Type: Article

References (40)

1. Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 2003; 308: 698-705.
2. Feldman DL, Jin L, Xuan H et al. Effects of aliskiren on blood pressure, albuminuria, and (pro) renin receptor expression in diabetic TG (mRen-2)27 rats. Hypertension 2008; 52: 130-6.
3. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalapril. Hypertension 2002; 39: e1-8.
4. 1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. 2004; 15: 3126-33.
5. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-76.
6. Fischer R, Dechend R, Qadri F et al. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 2008; 51: 540-6.
7. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression. Comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008; 51: 1306-11.
8. Westermann D, Riad A, Lettau O et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008; 52: 1068-75.
9. van Esch JH, Moltzer E, van Veghel R et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J. Hypertens. 2010; 28: 2145-55.
10. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor is renoprotective in advanced experimental diabetic nephropathy. Diabetologia 2007; 50: 2398-404.
11. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 1995; 47: 25-49.
12. Liu YH, Yang XP, Sharov VG et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors. J. Clin. Invest. 1997; 99: 1926-35.
13. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J. Appl. Physiol. 1973; 34: 279-82.
14. Campbell DJ, Kladis A, Duncan A-M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 1993; 21: 155-65.
15. Campbell DJ, Kladis A, Duncan A-M. Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension 1993; 22: 513-22.
16. Johansen KB, Marstein S, Aas P. Automated method for the determination of angiotensin-converting enzyme in serum. Scand. J. Clin. Lab. Invest. 1987; 47: 411-4.
17. Simson JA, Rowell C, Barrett JM, King J, Chao J. Rat urinary kallikrein localization in kidney: Effects of fixation. Histochem. J. 1987; 19: 633-42.
18. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J. Histochem. Cytochem. 1997; 45: 1559-65.
19. Lehr HA, van der Loos CM, Teeling P, Gown AM. Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J. Histochem. Cytochem. 1999; 47: 119-26.
20. Ashley PL, MacDonald RJ. Tissue-specific expression of kallikrein-related genes in the rat. Biochemistry 1985; 24: 4520-7.
21. Inoue H, Fukui K, Miyake Y. Identification and structure of the rat true tissue kallikrein gene expressed in the kidney. J. Biochem. 1989; 105: 834-40.
22. Spillmann F, Van Linthout S, Schultheiss HP, Tschope C. Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. Curr. Opin. Nephrol. Hypertens. 2006; 15: 22-9.
23. Park SS, Zhao H, Mueller RA, Xu Z. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3β. J. Mol. Cell. Cardiol. 2006; 40: 708-16.
24. 2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc. Res. 2007; 73: 130-42.
25. Yao YY, Yin H, Shen B, Chao L, Chao J. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul. Pept. 2007; 140: 12-20.
26. McDonald KM, Mock J, D'Aloia A et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995; 91: 2043-8.
27. Linz W, Wiemer G, Scholkens BA. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am. J. Cardiol. 1997; 80 (Suppl. 3A): A118-23.
28. Gallagher AM, Yu H, Printz MP. Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension 1998; 32: 84-8.
29. Tschesche H, Michaelis J, Kohnert U, Fedrowitz J, Oberhoff R. Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. Adv. Exp. Med. Biol. 1989; 247A: 545-8.
30. Sealey JE, Atlas SA, Laragh JH, Oza NB, Ryan JW. Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin. Nature 1978; 275: 144-5.
31. Maruta H, Arakawa K. Confirmation of direct angiotensin formation by kallikrein. Biochem. J. 1983; 213: 193-200.
32. Krivoy N, Schlüter H, Karas M, Zidek W. Generation of angiotensin II from human plasma by tissue kallikrein. Clin. Sci. 1992; 83: 477-82.
33. Ideishi M, Sasaguri M, Ikeda M, Arakawa K. Angiotensin-converting activity of tissue kallikrein. Nephron 1990; 55 (Suppl. 1): 62-4.
34. Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008; 51: 15-8.
35. Campbell DJ, Nussberger J, Stowasser M et al. Activity assays and immunoassays for plasma renin and prorenin: Information provided and precautions necessary for accurate measurements. Clin. Chem. 2009; 55: 867-77.
36. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-49.
37. Duncan A-M, Burrell LM, Kladis A, Campbell DJ. Effects of angiotensin converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J. Cardiovasc. Pharmacol. 1996; 28: 746-54.
38. Yousef GM, Diamandis EP. An overview of the kallikrein gene families in humans and other species: Emerging candidate tumour markers. Clin. Biochem. 2003; 36: 443-52.
39. Lundwall A, Band V, Blaber M et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 2006; 387: 637-41.
40. Duncan A-M, Kladis A, Jennings GL, Dart AM, Esler M, Campbell DJ. Kinins in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000; 278: R897-904.